title: Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients.
abstract: We report the clinical history of a female affected by advanced colorectal cancer (CRC). The patient was treated with five subsequent therapeutic schedules (FOLFIRI, FOLFOXIRI, FOLFIRI, FOLFOX4, FOLFOX4 plus cetuximab) because of the progression of the disease. The sixth treatment was bevacizumab in combination with 5-fluorouracil and irinotecan (FOLFIRI). The CT scan and the FDG-PET/CT performed 3 months after the beginning of the treatment showed that some, even if not all, lesions had a reduction of both size and metabolic activity. After the second revaluation the disease progressed. This short report suggests that the response of CRC to antiangiogenetic therapy may also occur after several unsuccessful antineoplastic treatments. Different biological features may explain the nonhomogeneous objective response of the metastatic lesions. Molecular imaging techniques seem to be mandatory in the era of tailored therapy since it is useful to have an in vivo 'biological picture' of the neoplastic disease.
authors.affiliation: Institute of Hematology and Medical Oncology 'L. and A. Seragnoli', University of Bologna, Bologna, Italy. gbrandi@med.unibo.it
authors.forename: G
authors.initials: G
authors.lastname: Brandi
authors.forename: M
authors.initials: M
authors.lastname: Nannini
authors.forename: M A
authors.initials: MA
authors.lastname: Pantaleo
authors.forename: S
authors.initials: S
authors.lastname: Fanello
authors.forename: M
authors.initials: M
authors.lastname: Farsad
authors.forename: S
authors.initials: S
authors.lastname: Fanti
authors.forename: G
authors.initials: G
authors.lastname: Ercolani
authors.forename: A
authors.initials: A
authors.lastname: Maleddu
authors.forename: M
authors.initials: M
authors.lastname: Di Battista
authors.forename: G
authors.initials: G
authors.lastname: Biasco
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D007167:Immunotherapy; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D015898:Tomography Scanners, X-Ray Computed
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab